Loading
SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Pasireotide. Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.81, genetic association 0.00, clinical 0.91). In OnCo, 1 product record names it (Pasireotide).
In plain words · SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
SSTR5 (Somatostatin receptor type 5) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Neuroendocrine tumours.
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
No product in this corpus aims at SSTR5 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Tumour-associated overexpression: HPA finds the RNA tissue enhanced in normal adrenal gland, blood vessel, heart muscle, kidney, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA SSTR5: RNA tissue enhanced (adrenal gland 2 nTPM, blood vessel 3 nTPM, heart muscle 2 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours); approvals of single-target medicines aimed at it also list Brain and spinal cord tumours (all types), not counted; Open Targets associates it with 1 specific cancer type at or above 0.5 (carcinoid tumor). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SSTR5 tissue; Human Protein Atlas SSTR5 pathology; Open Targets ENSG00000162009 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Yamada et al, Biochem. Biophys. Res. Commun, 1993, "Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype". Source.
Sources: HGNC HGNC:11334 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35346 (protein name, function text, keywords and locations (REST API)); CIViC gene SSTR5 (1 evidence items, 0 assertions, 2 variants; diseases: Neuroendocrine Tumour (GraphQL API, CC0)); Open Targets ENSG00000162009 (association with cancer (MONDO_0004992) 0.58; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.60 (GraphQL API, CC0))
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerisation. Location: Cell membrane (UniProt). Locus 16p13.3 (HGNC).
RNA: tissue enhanced (adrenal gland 2 nTPM, blood vessel 3 nTPM, heart muscle 2 nTPM, kidney 4 nTPM, pituitary gland 2 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA SSTR5 tissue · HPA SSTR5 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SSTR5" OR ABSTRACT:"SSTR5" OR TITLE:"somatostatin receptor 5" OR ABSTRACT:"somatostatin receptor 5" OR TITLE:"Somatostatin receptor type 5" OR ABSTRACT:"Somatostatin receptor type 5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSTR5, not a curated reading list.